Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>Products>This Product

LeadCare® II

Product Image
Product Description

LeadCare® II is the only CLIA-waived, point-of-care lead testing system that makes it possible to test, educate and intervene on-the-spot, in one visit. No need to send patients to an outside lab. No need to re-test due to sample problems at the lab. No risk of losing track of a child who needs treatment.

Who should be tested?

Federal law requires that all Medicaid eligible children be tested at 12 and 24 months and ages 36 to 72 months if they have not previously been tested.

Each state has guidelines for blood lead testing.  The American  Academy of Pediatrics (AAP) recommends that “children should be tested at least once when they are 2 years of age or, ideally, twice, at 1 and 2 years of age, unless lead exposure can be confidently excluded.”4

Contact us for information to help you determine your state’s specific testing requirements.

Who is at risk for lead exposure? Children are considered at risk if any of the following are true4:
•    Child lives in or frequently visits a home built before 1950, or a recently renovated home built before 1978
•    Child has a sibling or frequent playmate with elevated blood lead levels
•    Child's parent or primary caregiver works with lead. Examples include: battery recycling or manufacture, lead smelting, lead mining, auto repair, shipbuilding, construction, plumbing, and glass manufacture5
•    Child is a recent immigrant, refugee, or foreign adoptee.
•    Child has a household member who uses traditional, folk, or ethnic remedies or cosmetics or who routinely eats food imported informally (e.g., by a family member)

No safe levels. Evidence continues to grow that blood lead levels as low as 5 ug/dL may impair cognition3, with no minimum threshold yet identified.

Lifelong consequences of lead exposure include:
•    Six times higher likelihood of having a reading disability6
•    Being seven times more likely to drop out of high school6
•    Lower scores on neurobehavioral development7
•    Lower scores on tests for math, reading, nonverbal reasoning and short term memory7
•    Hypertension that contributes to adult cardiovascular disease8
•    Decline in IQ with every 1.0 μg/dL increase in blood lead9

Early diagnosis helps to quickly address the effects of lead exposure and provides impetus for lead abatement in homes.

LeadCare II is the only CLIA-waived point-of-care blood lead testing system. Employees of an office or lab operating under a CLIA Certificate of Waiver can administer the test.

Product LeadCare® II
Company Magellan Diagnostics
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Magellan Diagnostics
101 Billerica Ave, Building 4 North Billerica, MA 01862 USA

Tel: +1 800-959-5095
Fax: +1 800-755-5095

Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos